Clinical trials: Oral Anticoagulant
Drug Monitoring, Anticoagulants
Plasma Concentration Monitoring of Direct Oral Anticoagulants in Emergency Department Patients: Comparison of Two Laboratory Methods
The goal of this observational study is to learn whether two laboratory tests give the same results when measuring blood levels of blood thinners.
- Conditions
- Drug Monitoring, Anticoagulants, Factor Xa Inhibitors, Direct Oral Anticoagulants (DOACs)
- Trial name
- Plasma Concent (NCT07917455)
- Where
- 2 sites in Italy
- Volunteers
- 142 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Acute Coronary Syndrome, Myocardial Infarction
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter
- Trial name
- WOEST-3 (NCT04436978)
- Testing
- 30-day DAPT, Guideline-directed therapy
- Where
- 20 sites in Belgium, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- St. Antonius Hospital
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Non-valvular Atrial Fibrillation
Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation
In a population of patients with non-valvular atrial fibrillation (NVAF), and treated with oral anticoagulants (OAC) in routine clinical practice in England, this study will describe patients treated with each OAC, and to…
- Trial name
- NCT03002740
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke, Intracranial Hemorrhages
Novel Oral Anticoagulants in Stroke Patients
The present study will monitor and explore acute neurovascular emergencies in patients treated with NOACs compared to those under treatment with VKAs.
- Trial name
- NOACISP (NCT02353585)
- Where
- Switzerland
- Volunteers
- 1,050 people
- Sponsor
- University Hospital, Basel, Switzerland
Tooth Extraction
Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction
In patients treated with direct oral anticoagulants, bleeding events during or after tooth extraction can lead to unscheduled interruption of the antithrombotic treatment and a potential increased risk of thrombo-embolic events.
- Trial name
- EXTRACT-NOAC (NCT03413891)
- Testing
- Tranexamic Acid
- Where
- Belgium
- Volunteers
- 222 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Myeloproliferative Neoplasm
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Patients with myeloproliferative neoplasms (MPN) are predisposed to have an increased thrombotic and hemorrhagic risk and, in this context, the use of newly approved direct oral anticoagulants (DOACs) may have improved bleeding…
- Trial name
- MPN-DOACs (NCT04192916)
- Testing
- DOACs
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 442 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Deep Vein Thrombosis
Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants
ABSTRACT Background The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain .
- Trial name
- DACUS (NCT00438230)
- Testing
- Warfarin
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
Atrial Fibrillation, Obesity
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who…
- Conditions
- Atrial Fibrillation, Obesity, Anticoagulants
- Trial name
- NCT04681482
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 107,383 people
- Sponsor
- Pfizer
Nonvalvular Atrial Fibrillation
Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation
The purpose of this study is to establish a benchmark for rate of prescription of oral anticoagulants (OA) in patients with non-valvular atrial fibrillation (NVAF) seen in an ambulatory care setting, based on independent medical…
- Trial name
- BOAT-AF (NCT02919982)
- Where
- 21 sites in United States
- Volunteers
- 817 people
- Sponsor
- Baim Institute for Clinical Research
Mechanical Aortic and/or Mitral Valve Replacement Operation
Patient International Normalised Ratio (INR) Self-Testing Program
The aims of the study are to prove correlation between laboratory and patient self-testing (PST) measurements, estimation of INR variability within a target therapeutic zone and frequency of hemorrhagic and/or thromboembolic…
- Trial name
- NCT00925197
- Testing
- INR self-testing program
- Volunteers
- 206 people
- Sponsor
- University Hospital, Clermont-Ferrand
Cardiac Surgery
Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education
To meet the wishes of the Ministry of Health, the division of Cardiology University Hospital of Clermont Ferrand, combining the cardiology and cardiac surgery department, has developed since January 2009, a therapeutic education…
- Trial name
- EDUCA (NCT01699282)
- Testing
- VKA (antivitamin K) education, conventional hospital education
- Where
- France
- Volunteers
- 186 people
- Sponsor
- University Hospital, Clermont-Ferrand
Atrial Fibrillation (AF)
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
The purpose of the PAUSE-Virtual Study is to show that by changing pre-surgery visits with patients taking a blood thinner (direct oral anticoagulant (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) when the participant…
- Trial name
- PAUSEVirtual (NCT06844227)
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 1,780 people
- Sponsor
- McMaster University
Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive
Start or STop Anticoagulants Randomised Trial (SoSTART)
Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation…
- Conditions
- Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage, Subdural Hematoma
- Trial name
- SoSTART (NCT03153150)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- 67 sites in United Kingdom
- Volunteers
- 203 people
- Sponsor
- University of Edinburgh
Simulation Training, Anticoagulant Drugs
E-learning to Improve Oral Anticoagulant Use in Hospitalized Older People With AF
Atrial Fibrillation (AF) is the most common cardiac arrhythmia and the main cause of cardioembolic stroke. Oral Anticoagulation (OAC) has been shown to significantly prevent AF-related thromboembolism, however, despite convincing…
- Conditions
- Simulation Training, Anticoagulant Drugs, Elderly, Atrial Fibrillation
- Trial name
- SIM-AF (NCT03188211)
- Testing
- E-learning educational program, Control
- Where
- 20 sites in Italy
- Volunteers
- 247 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Coronary Artery Disease, Bleeding
Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures
Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction
- Trial name
- DOAC-NOSTOP (NCT05292846)
- Testing
- Direct-acting oral anticoagulation
- Where
- 4 sites in Italy, Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitario La Fe
Anticoagulants, Thromboembolism
Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
Vitamin K antagonists were hampered by several disadvantages, such as the need for frequent monitoring. In this context, new oral anticoagulants (NOACs) have been developed and are now available on the market.
- Conditions
- Anticoagulants, Thromboembolism, Hemorrhage
- Trial name
- Pgp NACO (NCT02103101)
- Testing
- Measurement of Plasma Concentrations of NOACs, Identification of ABCB1 polymorphisms coding for P-gp
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Transcatheter Aortic Valve Replacement
Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)
The main objective of this study is to demonstrate that a single anticoagulant therapy is superior to a combination of anticoagulant and antiplatelet therapy on the net clinical benefit estimated at 12 months after a…
- Trial name
- AVATAR (NCT02735902)
- Testing
- Vitamin K antagonist or direct oral anticoagulant treatment, Aspirin
- Where
- 6 sites in France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Atrial Fibrillation, Deep Vein Thrombosis
Pilot Study: Comparison of Patients' Knowledge of Direct Oral Anticoagulants in Post-hospitalization Between 2 Cardiology Departments Offering or Not a Pharmaceutical Interview During Hospitalization
Direct oral anticoagulants (Rivaroxaban, Apixaban and Dabigatran) are an alternative to anti-vitamin K drugs and low molecular weight heparins in many cardiovascular diseases.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- EDUC-AOD (NCT04674202)
- Testing
- Phone interview
- Where
- 2 sites in France
- Volunteers
- 154 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Anticoagulant Disorders
Management of Direct Oral Anti-Coagulants (DOACs) for Gastrointestinal Endoscopy Procedures
The use of Direct Oral Anti-Coagulants (DOACs) is expanding, but their proper management in patients undergoing endoscopic procedures is still not completely clear. Current European guidelines are based on weak data.
- Trial name
- NCT02734316
- Testing
- endoscopic procedure
- Where
- Italy
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- Valduce Hospital